Advertisement

Topics

Cydan Company Profile

11:31 EDT 25th September 2018 | BioPortfolio

Cydan is an orphan drug accelerator that identifies and de-risks assets with therapeutic and commercial potential. The accelerator’s model evaluates programs for treating rare diseases with high unmet medical need and is aimed at creating new companies to develop those therapies. Cydan was launched in 2013 by a management team with extensive drug development and commercialization experience and with financing from leading investors NEA, Pfizer Venture Investments and Alexandria Real Estate Equities. The accelerator is based in Cambridge, Mass. For more information, please visit www.cydanco.com.


News Articles [3 Associated News Articles listed on BioPortfolio]

Cydan Appoints Chief Business Officer

Healthcare investment professional and rare disease advocate strengthens leadership team Imran Babar to help company continue accelerating new treatments...

Cydan Awards Four Scholarships to Support Innovations Impacting Individuals with Rare Conditions

Partners with 2018 MassChallenge to Recognize and Support Life Science Pioneers Cydan II Inc., an orphan drug accelerator dedicated to creating therap...

Cydan Development Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 13042018] Prices from USD $250

SummaryCydan Development Inc Cydan is an orphan drug accelerator that conducts orphan drug programs with therapeutic and commercial potential. The company identifies assets with biology and proofofcon...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [4 Associated Companies listed on BioPortfolio]

Cydan

Cydan is an orphan drug accelerator that identifies and de-risks assets with therapeutic and commercial potential. The accelerator’s model evaluates programs for treating rar...

Cydan Development, Inc.

Cydan is an orphan drug accelerator that identifies and de-risks orphan drug products with significant therapeutic and commercial potential. The accelerator’s business model ...

Cydan, LLC

Cydan is an orphan drug accelerator that identifies and de-risks assets with therapeutic and commercial potential. The accelerator’s model evaluates programs for treating rar...

Imara Inc.

Imara Inc., a Cydan Development company, is dedicated to developing novel therapeutics for patients with sickle cell disease. Imara is developing IMR-687, a highly s...

More Information about "Cydan" on BioPortfolio

We have published hundreds of Cydan news stories on BioPortfolio along with dozens of Cydan Clinical Trials and PubMed Articles about Cydan for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cydan Companies in our database. You can also find out about relevant Cydan Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...


Corporate Database Quicklinks



Searches Linking to this Company Record